Provided by Tiger Trade Technology Pte. Ltd.

OnKure Therapeutics, Inc.

3.94
+0.01000.25%
Post-market: 3.940.00000.00%19:12 EDT
Volume:59.91K
Turnover:237.11K
Market Cap:159.16M
PE:-1.13
High:4.07
Open:3.95
Low:3.90
Close:3.93
52wk High:5.38
52wk Low:2.23
Shares:40.40M
Float Shares:33.68M
Volume Ratio:0.36
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4954
EPS(LYR):-4.4035
ROE:-46.91%
ROA:-29.26%
PB:0.92
PE(LYR):-0.89

Loading ...

Company Profile

Company Name:
OnKure Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
45
Office Location:
6707 Winchester Circle,Suite 400,Boulder,Colorado,United States
Zip Code:
80301
Fax:
- -
Introduction:
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Directors

Name
Position
Nicholas A. Saccomano
Chief Executive Officer and Director and President
Andrew Phillips
Director
Edward T. Mathers
Director
Isaac Manke
Director
Michael Grey
Director
R. Michael Carruthers
Director
Valerie M. Jansen
Director

Shareholders

Name
Position
Nicholas A. Saccomano
Chief Executive Officer and Director and President
Jason Leverone
Chief Financial Officer
Dylan Hartley
Chief Scientific Officer
Samuel Agresta
Chief Medical Officer